KRAS and non-small cell lung carcinoma: A recent study found that in NSCLC, KRAS mutations were closely associated with confirmed biomarkers of immunotherapy, including the tumor mutation burden, programmed death-ligand 1 (PD-L1) and tumor-infiltrating lymphocytes.